NDLI: Specific peripheral miRNA profiles for distinguishing lung cancer from COPD.

Please wait, while we are loading the content...

A phase II study of amrubicin and topotecan combination therapy in patients with relapsed or extensive-disease small-cell lung cancer: Okayama Lung Cancer Study Group Trial 0401.

Phase II study of S-1 monotherapy in platinum-refractory, advanced non-small cell lung cancer.

Phase I study of concurrent chemoradiation with pemetrexed and cisplatin followed by consolidation pemetrexed for patients with unresectable stage III non-small cell lung cancer.

Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers.

5-Aminolevulinic acid-induced fluorescence diagnosis of pleural malignant tumor.

Use of G-CSF during concurrent chemotherapy and thoracic radiotherapy in patients with limited-stage small-cell lung cancer safety data from a phase II trial.

Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed.

Exploration of the volumetric composition of human lung cancer nodules in correlated histopathology and computed tomography.

Adenosquamous lung carcinomas: a histologic subtype with poor prognosis.

Impact of histology on survival of resected non-small cell lung cancer (NSCLC) receiving adjuvant chemotherapy: subgroup analysis of the adjuvant vinorelbine (NVB) cisplatin (CDDP) versus observation in the ANITA trial.

Overexpression of MAD2 predicts clinical outcome in primary lung cancer patients.

Differences in adverse events between 250 mg daily gefitinib and 150 mg daily erlotinib in Japanese patients with non-small cell lung cancer.

Efficacy of bevacizumab (Bev) plus chemotherapy (CT) compared to CT alone in previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC): systematic review and meta-analysis.

Treatment of lung cancer patients and concomitant use of drugs interacting with cytochrome P450 isoenzymes.

Specific peripheral miRNA profiles for distinguishing lung cancer from COPD.

Pleiomorphic adenoma gene-like 2 expression is associated with the development of lung adenocarcinoma and emphysema.

Plasma versus serum levels of osteopontin and mesothelin in patients with malignant mesothelioma--which is best?

Preoperative CYFRA 21-1 and CEA as prognostic factors in patients with stage I non-small cell lung cancer.

Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry.

Frequency and clinicopathologic correlates of KRAS amplification in non-small cell lung carcinoma.

Tissue sampling in lung cancer: a review in light of the MERIT experience.

Do all lung adenocarcinomas follow a stepwise progression?

Primary pulmonary cancer colliding with metastatic breast carcinoma: hitherto unreported cases of cancer-to-cancer metastasis focusing on clinical implications.

Year: 2011 Volume: 73

Year: 2011 Volume: 72

Year: 2011 Volume: 71

Year: 2010 Volume: 70

Year: 2010 Volume: 69

Year: 2010 Volume: 68

Year: 2010 Volume: 67

Year: 2009 Volume: 66

Year: 2009 Volume: 65

Year: 2009 Volume: 64

Year: 2009 Volume: 63

Year: 2008 Volume: 62

Year: 2008 Volume: 61

Year: 2008 Volume: 60

Year: 2008 Volume: 59

Year: 2007 Volume: 58

Year: 2007 Volume: 57

Year: 2007 Volume: 56

Year: 2007 Volume: 55

Year: 2006 Volume: 54

Year: 2005 Volume: 49

Year: 2005 Volume: 48

Specific peripheral miRNA profiles for distinguishing lung cancer from COPD.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Leidinger, Petra Keller, Andreas Borries, Anne Huwer, Hanno Rohling, Mareike Huebers, Junko Lenhof, Hans-Peter Meese, Eckart
Description	Country affiliation: Germany Author Affiliation: Leidinger P ( Institute of Human Genetics, Saarland University, Medical School, Homburg, Germany.)
Abstract	Recently we reported differential miRNA signatures in blood cells of lung cancer patients and healthy controls. With the present study we wanted to investigate if miRNA blood signatures are also suited to differentiate lung cancer patients from COPD patients. We compared the expression of 863 human miRNAs in blood cells of lung cancer patients, COPD patients, and healthy controls. The miRNA pattern from patients with lung cancer and COPD were more similar to each other than to the healthy controls. However, we were able to discriminate lung cancer patients and COPD patients with 90.4% accuracy, 89.2% specificity, and 91.7% sensitivity. In total, 140 miRNAs were significant for the comparison COPD and controls, 61 miRNAs were significant for the comparison lung cancer and controls, and 14 miRNAs were significant for the comparison lung cancer and COPD. Screening target databases yielded over 400 putative targets for those 14 miRNAs. The predicted mRNA targets of three of the 14 miRNAs were significantly up-regulated in PBMCs of lung cancer patients compared to patients with non-malignant lung diseases. In conclusion, we showed that blood miRNA signatures are suitable to distinguish lung cancer from COPD.
File Format	HTM / HTML
ISSN	01695002
Issue Number	1
Volume Number	74
e-ISSN	18728332
Journal	Lung Cancer
Language	English
Publisher	Elsevier
Publisher Date	2011-10-01
Publisher Place	Ireland
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Oncology Tumor Markers, Biological Metabolism Carcinoma Diagnosis Genetics Leukocytes, Mononuclear Lung Neoplasms Micrornas Pulmonary Disease, Chronic Obstructive Aged Aged, 80 And Over Pathology Physiopathology Diagnosis, Differential Disease Progression Female Gene Expression Profiling Gene Expression Regulation, Neoplastic Humans Male Microarray Analysis Middle Aged Neoplasm Metastasis Predictive Value Of Tests Sensitivity And Specificity Journal Article Research Support, Non-u.s. Gov't
Content Type	Text
Resource Type	Article
Subject	Pulmonary and Respiratory Medicine Cancer Research Oncology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

MicroRNA expression profiles in the progression of prostate cancer--from high-grade prostate intraepithelial neoplasia to metastasis.

A chronic obstructive pulmonary disease related signature in squamous cell lung cancer.

Identification of a 5-gene signature panel for the prediction of prostate cancer progression.

Pulmonary MicroRNA Changes Alter Angiogenesis in Chronic Obstructive Pulmonary Disease and Lung Cancer

Clinical evaluation of microRNA expression profiling in non small cell lung cancer.

Differential microRNA expression profiles in HCT116 colorectal cancer cell lines located in the lung and colon.

Gene expression profiling of non-small cell lung cancer.

The expression of miR-25 is increased in colorectal cancer and is associated with patient prognosis.

MiR-215/192 participates in gastric cancer progression.

Specific peripheral miRNA profiles for distinguishing lung cancer from COPD.

Similar Documents

MicroRNA expression profiles in the progression of prostate cancer--from high-grade prostate intraepithelial neoplasia to metastasis.

A chronic obstructive pulmonary disease related signature in squamous cell lung cancer.

Identification of a 5-gene signature panel for the prediction of prostate cancer progression.

Pulmonary MicroRNA Changes Alter Angiogenesis in Chronic Obstructive Pulmonary Disease and Lung Cancer

Clinical evaluation of microRNA expression profiling in non small cell lung cancer.

Differential microRNA expression profiles in HCT116 colorectal cancer cell lines located in the lung and colon.

Gene expression profiling of non-small cell lung cancer.

The expression of miR-25 is increased in colorectal cancer and is associated with patient prognosis.

MiR-215/192 participates in gastric cancer progression.

Specific peripheral miRNA profiles for distinguishing lung cancer from COPD.